Head-to-head · WeighScore
Ageless vs Luma Health Co
The verdict
Ageless takes it — 84.8/100 to 74.8/100.
Ageless grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. One of the broadest compounded storefronts on the board — GLP-1, NAD+, sermorelin, TRT and more under one roof, in both injectable and oral routes, on low headline pricing (semaglutide $119/mo, tirzepatide $169/mo) — offset by a compounded-only catalog and an undisclosed state list.
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | Ageless | Luma Health Co |
|---|---|---|
| WeighScore | 84.8/100 | 74.8/100 |
| Grade | B | C |
| Scorecard rank | #10 | #62 |
| Semaglutide | $119/mo | $120/mo (plus a separate fee, compounded) |
| Tirzepatide | $169/mo | $180/mo (compounded) |
| Coverage | Varies by state | 30 states |
| Brand-name access | Compounded only | Compounded only |
| Oral / sublingual | Yes | Injection only |
Graded #10 · B
Strengths
- Unusually broad compounded menu — GLP-1, NAD+, sermorelin, TRT, LDN and more, in both injectable and oral formats
- Low headline GLP-1 pricing — semaglutide $119/mo, tirzepatide $169/mo — no insurance, with Klarna/Affirm financing
- Fully online: licensed-clinician review and discreet delivery, with upfront compounded/not-FDA disclosures
- Oral routes available (drops and troches), not injection-only
Where it loses points
- Everything is compounded and not FDA-approved — not equivalent to brand Wegovy/Ozempic/Zepbound
- Oral GLP-1 drops and troches lack robust absorption/efficacy evidence versus injectables
- No published state-availability list and no named legal entity or medical group
- Thin public track record, and advertised prices are floors set after clinical review
Graded #62 · C
Strengths
- Transparent, competitive pricing published up front — compounded semaglutide from $120/mo, tirzepatide from $180/mo, retatrutide from $170/mo
- No subscription, monthly fee or membership — a direct-to-patient model where you pay per medication, and follow-up visits are free
- Free initial consults for first responders, law enforcement, military, nurses and teachers ($0), and $25 for other healthcare workers
- Founded and led by a named family nurse practitioner (Tiffani McKnight, FNP-C) licensed across 30 states/DC, with HIPAA-compliant virtual visits
- HSA/FSA funds and financing accepted, with itemized invoices for HSA/FSA submission
Where it loses points
- Offers compounded retatrutide (labeled "RTT/GLP-3"), an investigational triple agonist not FDA-approved — a higher-risk, less-studied option
- Compounded medications only — no brand-name Wegovy, Zepbound or Ozempic — and compounded GLP-1s aren't FDA-reviewed or approved
- No LegitScript certification shown and no compounding-pharmacy partner named, so the dispensing pharmacy can't be independently verified
- Small, newly established founder-led practice with a thin website and limited public track record or third-party reviews
- Medication prices are "starting at" and billed on top of a one-time consult fee, so the true first-month cost runs higher than the headline
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.